BioDelivery Sciences is a specialty pharma company that is focused on large market opportunities in pain and addiction. Their current product portfolio is mostly derived from their patented BioErodible MucoAdhesive (BEMA) film technology, which they apply to existing drugs allowing them to follow the cost- and time- efficient 505(b)2 FDA approval pathway for reformulations. BEMA is a thin-film drug carrier that adheres to the inner cheek to efficiently deliver drugs to the oral mucosa offering rapid, non-invasive delivery with several advantages over existing mucosal products including better pharmacokinetics and bioavailability.

BioDelivery Sciences has multiple approved and late-stage assets that Foresite Capital believes will continue to drive value in both the near- and long-term.